The in vitro activity of N-formimidoyl thienamycin (N-f-thienamycin) was compared with the activities of other ,B-lactam antibiotics, using over 500 clinical bacterial isolates. N-f-Thienamycin inhibited 90% of the isolates of the common Enterobacteriaceae between 0.06 and 2 ,Ag/ml, regardless of their resistance to amoxicillin, ticarcillin, or cephalothin. It was, however, fourfold less active than moxalactam and ceftazidime and eightfold less active than cefotaxime. N-f-Thienamycm was nearly as active as ceftazidime against Pseudomonas aeruginosa (mean minimal inhibitory concentration, 3.0 ,ug/ml) and eightfold more active than cefotakime and moxalactam. In contrast to cefotaxime, moxalactam, and ceftazidime, N-f-thienamycin was highly active against enterococci (mean minimal inhibitory concentration, 1.3 ,ug/ml) and staphylococci. The oxacillin-susceptible Staphylococcus aureus were inhibited between 0.03 and 0.12 ug/ml, and the oxacillin-resistant S. aureus were inhibited between 0.12 and 2 ,g/rnl. The high activity of N-f-thienamycin against both of the most important gram-positive and gram-negative organisms makes it a very promising new antibiotic.
The in vitro activity of N-formimidoyl thienamycin (N-f-thienamycin) was compared with the activities of other ,B-lactam antibiotics, using over 500 clinical bacterial isolates. N-f-Thienamycin inhibited 90% of the isolates of the common Enterobacteriaceae between 0.06 and 2 ,Ag/ml, regardless of their resistance to amoxicillin, ticarcillin, or cephalothin. It was, however, fourfold less active than moxalactam and ceftazidime and eightfold less active than cefotaxime. N-f-Thienamycm was nearly as active as ceftazidime against Pseudomonas aeruginosa (mean minimal inhibitory concentration, 3 .0 ,ug/ml) and eightfold more active than cefotakime and moxalactam. In contrast to cefotaxime, moxalactam, and ceftazidime, N-f-thienamycin was highly active against enterococci (mean minimal inhibitory concentration, 1.3 ,ug/ml) and staphylococci. The oxacillin-susceptible Staphylococcus aureus were inhibited between 0.03 and 0.12 ug/ml, and the oxacillin-resistant S. aureus were inhibited between 0.12 and 2 ,g/rnl. The Table 1 . N-f-Thienamycin was the most active antibiotic against S. aureus and S. epidermidis, regardless of their resistance to penicillin G. Surprisingly, it retained a high activity against oxacillin-resistant isolates of S. aureus (mean MIC, 0.3 jg/ml), in contrast to all other f8-lactam antibiotics. N-f-Thienamycin The activity of N-f-thienamycin against Enterobacteriaceae was superior to the activities of amoxicillin, ticarcillin, and cephalothin, but it was two-to eightfold less active against most species than cefotaxime, moxalactam, and ceftazidime. N-f-Thienamycin was least active against the Proteus species, which were the species most susceptible to cefotaxime, moxalactam, and ceftazidime. In contrast, about 10% of the Enterobacter isolates were inhibited by the latter group of antibiotics only at concentrations equal to or exceeding 16 ,tg/ml, but they were susceptible to N-f-thienamycin at 4 ,ug/ml or less. The concentrations tested to inhibit 90% of the entire group of unselected Enterobacteriaceae were 0.5 ,tg/ml each of cefotaxime, moxalactam, and ceftazidime, and 2 ,ug/ml of N-fthienamycin.
N-f-Thienamycin was the most active antibiotic against Acinetobacter species, all strains being inhibited by 0.25 ,ug/ml. N-f-Thienamycin was very active against Pseudomonas aeruginosa (mean MIC, 3.0 ,ug/ml) and was surpassed in activity only by ceftazidime (mean MIC, 1.8 ,ig/ml), the most active ,B-lactam antibiotic against this species thus far known (6) . N-fThienamycin was also the most active antibiotic against Pseudomonas cepacia, Pseudomonas stutzeri, Pseudomonas putida, and Pseudomonas putrefaciens (MICs between 0.25 and 4 jig/ ml), but it was completely ineffective against Pseudomonas maltophilia (MIC 2 128 ,ug/ml).
The only active antibiotics against P. maltophilia were moxalactam (mean MIC, 5.4 ,ug/ml) and ceftazidime (mean MIC, 7.2 jg/ml).
To evaluate the relative activity of the new antibiotics against isolates susceptible or resistant to cephalothin, an additional number of selected cephalothin-resistant E. coli, Klebsiella, and P. mirabilis isolates with proven production of 83-lactam antibiotics were examined.
The unselected isolates and the strains selected for cephalothin-resistance were subdivided into three groups: the cephalothin-susceptible organisms (breakpoint, MICso of the unselected population), the moderately resistant strains, and the highly resistant ones. In Table 2 the geometric mean and the range of the MICs are shown. Almost no difference was seen in the mean MICs of N-f-thienamycin between the most susceptible and the most resistant isolates to cephalothin in all three species. In contrast, the MICs of cefotaxime and ceftazidime against the highly resistant E. coli strains were about 40-fold higher than the MICs against the cephalothin-susceptible isolates.
Likewise, isolates of E. coli, P. mirabilis, Enterobacter, and P. aeruginosa have been subdivided into three groups according to their susceptibility to ticarcillin (Table 3) . Once again, almost no difference in activity of N-f-thienamycin was seen between isolates highly susceptible or highly resistant to ticarcillin within the species E. coli, P. mirabilis and Enterobacter, whereas cefotaxime, moxalactani, and ceftazidime showed about a 10-fold increase of MICs between the most susceptible and the most resistant Enterobacter isolates. With P. aeruginosa isolates, the increase in MICs of all four antibiotics against highly ticarcillin-resistant isolates was less than fourfold.
DISCUSSION
This study demonstrates that N-f-thienamycin is a highly active broad-spectrum antibiotic, against both gram-positive cocci and gram-negative bacilli, regardless of their resistance to other fi-lactam antibiotics. The activity of N-fthienamycin was not affected by the presence of fl-lactamases in those isolates in which they were produced. Our results are very similar to the data reported by other investigators (1, 2, 3, 5) . In this study, 531 of the 538 isolates, including gram-positive cocci, Enterobacteriaceae, and nonfernenters isolated from clinical specimens in a teaching hospital, were inhibited by a concentration of 8 ,ug/ml of N-f-thienamycin. Only the seven P. maltophilia isolates were resistant. From these in vitro results, N-f-thienamycin appears to be highly competitive with cefotaxime, moxalactam, and ceftazidime; it is somewhat less active againstthe Enterobacteriaceae, very similar in activity to ceftazidime against P. aeruginosa, but substantially more active than the other three antibiotics against staphylococci and enterococci. Furthermore, Kropp et al. (3) and Tally et al. (5) reported that N-f-thienamycin was also highly active against obligate anaerobes. Therefore, N-f-thienamycin appears to be a very promising antibiotic which deserves further pharmacological and clinical evaluation.
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